Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Goodwin advised the initial purchasers on Amphastar Pharmaceuticals, Inc.’s offering. Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the Rule 144A offering of 2.00% Convertible Senior Notes due...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Avadel Pharmaceutics plc on the deal. Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised ACELYRIN on the deal. ACELYRIN announced the completion of its $300 million Series C financing round which was led by Access Biotechnology with participation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio on the deal. BridgeBio announced its definitive agreement with an undisclosed purchaser to sell its rare pediatric disease Priority Review Voucher for $110...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Emmet, Marvin & Martin, LLP, Giovannelli e Associati Studio Legale, Goodwin Procter, Loeb & Loeb LLP, Spada Partners, advised on the matter. Emmet, Marvin...
You must be a Standard 1 Year member to access this content.
